Hepatitis Monthly

Published by: Kowsar

The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection

Fatemeh Afsharzadeh 1 , Farah Bokharaei-Salim 1 , 2 , ** , Maryam Esghaei 1 , Seyed Hamidreza Monavari 1 , Shahin Merat 3 , Hossein Poustchi 3 , Arghavan Haj-Sheykholeslami 3 , 4 and Hossein Keyvani 1 , **
Authors Information
1 Department of Virology, Iran University of Medical Sciences, Tehran, IR Iran
2 HIV Laboratory of National Center, Deputy of Health, Iran University of Medical Sciences, Tehran, IR Iran
3 Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Community Medicine, Iran University of Medical Sciences, Tehran, IR Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: December 01, 2016, 16 (12); e42388
  • Published Online: December 11, 2016
  • Article Type: Research Article
  • Received: September 19, 2016
  • Revised: October 20, 2016
  • Accepted: November 29, 2016
  • DOI: 10.5812/hepatmon.42388

To Cite: Afsharzadeh F, Bokharaei-Salim F, Esghaei M, Monavari S H, Merat S, et al. The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection, Hepat Mon. 2016 ; 16(12):e42388. doi: 10.5812/hepatmon.42388.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Objectives
3. Methods
4. Results
4. Discussion
  • 1. Carcamo WC, Ceribelli A, Calise SJ, Krueger C, Liu C, Daves M, et al. Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients. J Clin Immunol. 2013; 33(2): 420-6[DOI][PubMed]
  • 2. Bastani MN, Bokharaei-Salim F, Keyvani H, Esghaei M, Monavari SH, Ebrahimi M, et al. Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol. 2016; 161(7): 1899-906[DOI][PubMed]
  • 3. Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG, et al. The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study. PLoS One. 2011; 6(8)[DOI][PubMed]
  • 4. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl)-57[DOI][PubMed]
  • 5. Bokharaei-Salim F, Keyvani H, Esghaei M, Zare-Karizi S, Dermenaki-Farahani SS, Hesami-Zadeh K, et al. Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection. J Med Virol. 2016; 88(11): 1960-6[DOI][PubMed]
  • 6. Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int. 2010; 14(3): 253-62[DOI][PubMed]
  • 7. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007; 132(5): 1979-98[DOI][PubMed]
  • 8. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 1993; 67(3): 1385-95[PubMed]
  • 9. Wu Q, Zhan FY, Chen EQ, Wang C, Li ZZ, Lei XZ. Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China. Hepat Mon. 2015; 15(6)[DOI][PubMed]
  • 10. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007; 20(1): 23-38[DOI][PubMed]
  • 11. Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1. Hepat Mon. 2015; 15(1)[DOI][PubMed]
  • 12. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010; 138(7): 2307-14[DOI][PubMed]
  • 13. Bokharaei-Salim F, Salehi-Vaziri M, Sadeghi F, Esghaei M, Monavari SH, Alavian SM, et al. The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNalpha-2a/RBV Combination Therapy in Azerbaijani Patients. Hepat Mon. 2016; 16(5)[DOI][PubMed]
  • 14. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB, Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of H. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007; 39(1): 2-17[DOI][PubMed]
  • 15. Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut. 2001; 48(3): 378-83[PubMed]
  • 16. Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 2013; 8(2)[DOI][PubMed]
  • 17. Fabbri C, Jaboli MF, Giovanelli S, Azzaroli F, Pezzoli A, Accogli E, et al. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol. 2003; 9(7): 1487-90[PubMed]
  • 18. Stinton LM, Myers RP, Coffin CS, Fritzler MJ. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. BMC Gastroenterol. 2013; 13: 50[DOI][PubMed]
  • 19. Takashi H, Mikio N. Autoantibodies in hepatitis C virus-related chronic liver disease. Hepat Mon. 2008; 2008(4, Autumn): 295-303
  • 20. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science. 1998; 282(5390): 938-41[PubMed]
  • 21. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014; 61(1 Suppl)-25[DOI][PubMed]
  • 22. Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol. 2009; 50(2): 402-11[DOI][PubMed]
  • 23. Carcamo WC, Satoh M, Kasahara H, Terada N, Hamazaki T, Chan JY, et al. Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS One. 2011; 6(12)[DOI][PubMed]
  • 24. Covini G, Carcamo WC, Bredi E, von Muhlen CA, Colombo M, Chan EK. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir Ther. 2012; 17(5): 805-11[DOI][PubMed]
  • 25. Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S, et al. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNalpha-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol. 2014; 86(9): 1499-506[DOI][PubMed]
  • 26. Bokharaei-Salim F, Keyvani H, Salehi-Vaziri M, Sadeghi F, Monavari SH, Mehrnoush L, et al. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNalpha-2a/RBV combination therapy in Azerbaijani patients. Arch Virol. 2014; 159(11): 2893-9[DOI][PubMed]
  • 27. Poordad FF, Flamm SL. Virological relapse in chronic hepatitis C. Antivir Ther. 2009; 14(3): 303-13[PubMed]
  • 28. Keppeke GD, Nunes E, Ferraz ML, Silva EA, Granato C, Chan EK, et al. Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-alpha. PLoS One. 2012; 7(9)[DOI][PubMed]
  • 29. Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon. 2013; 13(1)[DOI][PubMed]
  • 30. Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M. Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol. 1996; 7(1): 7-16[PubMed]
  • 31. Gregorio GV, Choudhuri K, Ma Y, Pensati P, Iorio R, Grant P, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol. 2003; 133(3): 404-13[PubMed]
  • 32. Felisberto M, Jorge AS, Menolli RA, Gnutzmann LV, Nesi V. Induction of cytoplasmic pattern in the form of "rods and rings" through the treatment of hepatitis C: a case report. Rev Bras Reumatol. 2015; 55(2): 181-4[DOI][PubMed]
  • 33. Seelig HP, Appelhans H, Bauer O, Bluthner M, Hartung K, Schranz P, et al. Autoantibodies against inosine-5'-monophosphate dehydrogenase 2--characteristics and prevalence in patients with HCV-infection. Clin Lab. 2011; 57(9-10): 753-65[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments